Your browser doesn't support javascript.
loading
Introducing the concept of virtual control groups into preclinical toxicology testing.
Steger-Hartmann, Thomas; Kreuchwig, Annika; Vaas, Lea; Wichard, Jörg; Bringezu, Frank; Amberg, Alexander; Muster, Wolfgang; Pognan, Francois; Barber, Chris.
Affiliation
  • Steger-Hartmann T; Bayer AG, Pharmaceuticals, Investigational Toxicology, Berlin, Germany.
  • Kreuchwig A; Bayer AG, Pharmaceuticals, Investigational Toxicology, Berlin, Germany.
  • Vaas L; Bayer AG, Pharmaceuticals, Investigational Toxicology, Berlin, Germany.
  • Wichard J; Bayer AG, Pharmaceuticals, Investigational Toxicology, Berlin, Germany.
  • Bringezu F; Merck Healthcare KGaA, Biopharma and Non-Clinical Safety, Darmstadt, Germany.
  • Amberg A; Sanofi, Preclinical Safety, Frankfurt, Germany.
  • Muster W; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland.
  • Pognan F; Novartis Institute for Biomedical Research, Basel Switzerland.
  • Barber C; Lhasa Ltd. Leeds, UK.
ALTEX ; 37(3): 343-349, 2020.
Article de En | MEDLINE | ID: mdl-32242633
ABSTRACT
Sharing legacy data from in vivo toxicity studies offers the opportunity to analyze the variability of control groups stratified for strain, age, duration of study, vehicle and other experimental conditions. Historical animal control group data may lead to a repository, which could be used to construct virtual control groups (VCGs) for toxicity studies. VCGs are an established concept in clinical trials, but the idea of replacing living beings with virtual data sets has so far not been introduced into the design of regulatory animal studies. The use of VCGs has the potential of a 25% reduction in animal use by replacing the control group animals with existing randomized data sets. Prerequisites for such an approach are the availability of large and well-structured control data sets as well as thorough statistical evaluations. the foundation of data sharing has been laid within the Innovative Medicines Initiatives projects eTOX and eTRANSAFE. For a proof of principle participating companies have started to collect control group data for subacute (4-week) GLP studies with Wistar rats (the strain preferentially used in Europe) and are characterizing these data for its variability. In a second step, the control group data will be shared among the companies and cross-company variability will be investigated. In a third step, a set of studies will be analyzed to assess whether the use of VCG data would have influenced the outcome of the study compared to the real control group.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Plan de recherche / Bases de données factuelles / Tests de toxicité / Diffusion de l'information / Évaluation préclinique de médicament Type d'étude: Clinical_trials Langue: En Journal: ALTEX Sujet du journal: MEDICINA Année: 2020 Type de document: Article Pays d'affiliation: Allemagne

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Plan de recherche / Bases de données factuelles / Tests de toxicité / Diffusion de l'information / Évaluation préclinique de médicament Type d'étude: Clinical_trials Langue: En Journal: ALTEX Sujet du journal: MEDICINA Année: 2020 Type de document: Article Pays d'affiliation: Allemagne